Resources
Scientific resources and analytical context
Explore the published heritage of automated particle Raman analysis and discuss the technical information relevant to your application.
A Systematic Approach in the Development of the Morphologically-Directed Raman Spectroscopy Methodology for Characterizing Nasal Suspension Drug Products
Farias et al.
Chemically specific API particle-size distributions in nasal sprays: submicron particles to agglomerates
Krapf, Laskina & Valet
Founder publication
The Use of High Throughput Raman Microscopy for the Concurrent Size Determination and Chemical Characterization of Inhalation Particles
Valet et al. · Respiratory Drug Delivery 2010
Founder publication
Foreign Particle Investigation & Contamination Control
2026
Pinpointing Contamination Sources: Evaluating AI Supported Spectroscopic Data Analysis Methods for Cellulose Fiber Contamination
Lankers, M. & Ivanov, L. (2026). PDA poster, Dublin, Ireland.
Original cellulose reference study: Raman identification and machine-learning-assisted differentiation of closely related sources. Read the complete scientific poster (PDF).
2025
Root cause analysis investigation of visible particulates in therapeutic protein drug products using morphologically directed Raman spectroscopy
de Luna, I.F. et al. · Scientific Reports 15, 42026 · DOI: 10.1038/s41598-025-97097-x
Recent MDRS study demonstrating combined morphological and chemical characterization for root-cause investigation of visible particulates in therapeutic protein drug products.
Chemical characterization of common foreign particulate contaminants in dry-powder inhalers
Valet
Founder publication
MDI foreign-particulate Raman method validation according to ICH parameters
Valet
Founder publication
Particle Explorer qualification for DPI foreign-particle counting and identification
Valet & Niemann
Founder publication
Integrated foreign-particle testing in OINDP
Niemann & Valet
Founder publication
2026
Control strategy for subvisible particulates of therapeutic protein injections in pre-filled syringes using flow imaging
Zhang, B. et al. · Journal of Pharmaceutical Sciences 115(3), 104168 · DOI: 10.1016/j.xphs.2026.104168
Flow-imaging control strategy for protein injectables with complementary Raman microscopy for chemical identification of silicone-oil particles.
2023
Morphologically-Directed Raman Spectroscopy as an Analytical Method for Subvisible Particle Characterization in Therapeutic Protein Product Quality
Kim, M. et al. · Scientific Reports 13, 20473 · DOI: 10.1038/s41598-023-45720-0
Application of MDRS to chemically characterize individual subvisible particles in therapeutic protein products and support root-cause analysis.
Subvisible particle identification in protein-based formulations by Raman spectroscopy
Lankers, Valet & Laskina
Founder publication
2015
Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway
Saggu, M.; Liu, J.; Patel, A. · Pharmaceutical Research 32, 2877–2888 · DOI: 10.1007/s11095-015-1670-x
Raman identification of insoluble fatty-acid particles links subvisible-particle formation to polysorbate-20 degradation pathways.
Non-destructive identification of particles in pharmaceutical products
Valet & Lankers
Founder publication
2024
Best Practices to Quantify and Identify Particulate Matter on the Interior Surfaces of Single-Use Systems
Wormuth, K. et al. · PDA Journal of Pharmaceutical Science and Technology 78, 90–99 · DOI: 10.5731/pdajpst.2022.012755
Best-practice framework for extracting, quantifying and chemically identifying particulate matter associated with single-use systems.
Particle identification in parenteral drug raw materials
Lee, Lankers & Valet
Founder publication
2026
Guideline on the pharmaceutical quality of inhalation and nasal medicinal products
EMA · EMEA/CHMP/QWP/49313/2005 Rev. 1 · Adopted guideline · Effective 1 February 2026
Sets quality expectations for inhalation and nasal medicinal products, including product-specific particle-size and performance considerations.
2018
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products — Quality Considerations
FDA · April 2018 draft · Nonbinding · Not for implementation
Section IV.F.7 proposes foreign-particulate tests and size-band acceptance criteria for MDI and DPI product specifications.
2022
European Commission EU GMP Annex 1: Manufacture of Sterile Medicinal Products
European Commission · Revised Annex 1 · In operation since 25 August 2023, with point 8.123 applicable since 25 August 2024
Sections 2 and 8 address contamination control in sterile manufacture, including inspection and investigation of defects in filled parenteral containers.
2003
FDA Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action
U.S. Food and Drug Administration · Draft guidance for industry · Revised: April 2003 · Not for implementation
The April 2003 draft discusses bioequivalence for locally acting nasal products and the role of drug particle-size characterization for nasal suspensions. Consult product-specific recommendations when planning a study.
USP–NF · Compendial chapter · Apply the edition and tests relevant to the product
Covers performance tests such as delivered-dose uniformity and particle-size testing, including aerodynamic sizing where applicable.
USP–NF · Compendial chapter · Revised text official 1 August 2026
Describes light-obscuration and microscopic counting for subvisible particulate matter in applicable parenteral preparations.
EDQM · Compendial chapter · Issue 13.1 revision takes effect 1 January 2027
Describes light-obscuration and microscopic counting for subvisible particles. Consult the applicable in-force Ph. Eur. text.
USP–NF · Compendial chapter
Sets out visual inspection and acceptance criteria for visible particulates in applicable injections.
USP–NF · Informational general chapter
Provides guidance on visual inspection of injections, including factors that affect detection and difficult-to-inspect products.
FDA · FDA-2021-D-0241 · December 2021 draft · Nonbinding · Not for implementation
Discusses visible particulate control for injectables, including particle identification, investigations and corrective actions. Subvisible particulates are outside its scope.
APSys / rap.ID developed an image-first workflow: automated microscopy located candidate particles before selective Raman measurement. Early patents combined detection, sizing and spectroscopic identification, anticipating the workflow later marketed as MDRS.
Historical patent references: DE 199 46 110 C1; PCT/EP00/07937; DE 101 27 537.4; DE 101 27 538.2.
Automated particle-identification patent family
2001 substrate patent record
1999 APSys patent record
The first stainless-steel, touchscreen-controlled prototype was released in 2001. Development now spans more than 25 years and seven instrument generations.
Historical rap.ID experience refers to the predecessor companies and laboratories. SizeID.bio is the current particle-analysis offering of mibiC GmbH & Co. KG.